Ocugen, Inc. OCGN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
2/9
Piotroski F — financial health
-40.32
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $4.4M | -$67.8M | — | -$57.1M | -$12.2M |
| 2024 | $4.1M | -$54.1M | — | -$45.5M | $29.6M |
| 2023 | $6.0M | -$63.1M | — | -$72.5M | $40.6M |
| 2022 | $2.5M | -$86.8M | — | -$64.5M | $74.0M |
| 2021 | $0 | -$58.4M | — | -$48.9M | $91.2M |
| 2020 | $43,000 | -$21.8M | — | -$15.0M | $21.6M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -40.32 (distress)
- Working capital / assets 0.03
- Retained earnings / assets -9.377
- EBIT / assets -1.446
- Equity / liabilities -0.218
Source: SEC EDGAR filings · CIK 0001372299 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.